Cost-Related Medication Nonadherence After the Inflation Reduction Act
In this difference-in-differences analysis, the IRA's 2024 prescription drug provisions were associated with a reduction in cost-related medication nonadherence among eligible Medicare beneficiaries in their first year. These early improvements may have important implications for chronic disease management and downstream clinical outcomes.
Authors
- Lucas Marinacci (ORCID: https://orcid.org/0000-0002-4443-2441)
- Stephen A. Mein (ORCID: https://orcid.org/0000-0002-6567-1564)
- Benjamin N. Rome (ORCID: https://orcid.org/0000-0001-5776-3293)
- Rishi K. Wadhera
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Deaconess Hospital (US)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1001/jamainternmed.2026.0012
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 0.00